Ketamine
Phencyclidine derivative; dissociative anaesthetic
Mechanism. Non-competitive NMDA receptor antagonist (blocks the open channel); also opioid, monoamine and muscarinic actions. Indirect sympathomimetic.
Kinetics. IV onset within a minute, duration 10 to 15 minutes; IM onset 3 to 5 minutes. Hepatic metabolism to active norketamine; high lipid solubility.
Dose. Induction: 1 to 2 mg/kg IV, less in shock.
Adverse effects.
- Emergence phenomena
- Hypersalivation, laryngospasm (rare)
- Hypertension, tachycardia; direct myocardial depression revealed when catecholamines are exhausted
- Vomiting on recovery
Airway reflexes and spontaneous breathing are usually preserved, but not guaranteed.
Analgesia at sub-dissociative doses; bronchodilator properties make it useful in asthma.
Propofol
Alkylphenol IV anaesthetic
Mechanism. Potentiates GABA-A receptors (prolonged Cl channel opening); at high doses directly activates them.
Kinetics. Lipid emulsion; onset in one arm-brain circulation time; offset by redistribution; hepatic and extrahepatic (lung) metabolism; context-sensitive half-time rises with infusion length.
Adverse effects.
- Hypotension (vasodilation and myocardial depression), apnoea
- Pain on injection
- Propofol infusion syndrome with prolonged high doses (acidosis, rhabdomyolysis, arrhythmia)
Reduce the dose sharply in shock and in the elderly; it lowers sympathetic tone.
Antiemetic and suppresses airway reflexes, which helps laryngeal mask insertion.
Midazolam
Benzodiazepine
Mechanism. Positive allosteric modulator at the benzodiazepine site of GABA-A (alpha-gamma interface): increases frequency of Cl channel opening.
Kinetics. Water soluble at acid pH (ring open), lipid soluble at body pH (ring closes), so painless IV and rapid brain entry. Hepatic CYP3A4 to active alpha-hydroxymidazolam, renally excreted. Half-life 2 to 4 hours. Effective IM, buccal and intranasal.
Adverse effects.
- Respiratory depression, worse with opioids and alcohol
- Hypotension
- Paradoxical agitation
- Prolonged effect in the elderly, in liver failure and with CYP3A4 inhibitors
Reversible with flumazenil, but flumazenil can precipitate seizures in benzodiazepine dependence or mixed overdose.
Suxamethonium
Depolarising neuromuscular blocker
Mechanism. Two acetylcholine molecules joined: binds nicotinic receptors and depolarises the endplate (fasciculation), then the junction stays depolarised and inexcitable (phase I block).
Kinetics. Onset 45 to 60 seconds; duration 5 to 10 minutes; hydrolysed by plasma cholinesterase (butyrylcholinesterase), not acetylcholinesterase.
Dose. Rapid sequence intubation: 1.5 mg/kg IV.
Adverse effects.
- Hyperkalaemia (about 0.5 mmol/L normally; life-threatening after burns, crush, denervation, prolonged immobility)
- Bradycardia (muscarinic), especially with repeat doses or in children
- Malignant hyperthermia trigger
- Prolonged block with cholinesterase deficiency
- Myalgia, raised intraocular and intragastric pressure
No reversal agent; you wait for it to wear off.
Rocuronium
Non-depolarising aminosteroid neuromuscular blocker
Mechanism. Competitive antagonist at the nicotinic acetylcholine receptor alpha subunits.
Kinetics. Onset about 60 seconds at high dose; duration 30 to 60 minutes or more; mainly biliary excretion unchanged, some renal.
Dose. Rapid sequence intubation: 1.2 mg/kg IV (ideal-to-total body weight practice varies).
Adverse effects.
- Anaphylaxis (one of the commoner causes of perioperative anaphylaxis)
- Awareness if sedation is not maintained
Reversed by sugammadex, which encapsulates it, or partly by neostigmine once some recovery has occurred.
Long duration means post-intubation sedation must be started promptly.
Morphine
Opioid; mu agonist
Mechanism. Mu receptor (Gi): opens K channels, closes voltage-gated Ca channels, reduces cAMP; reduces neurotransmitter release in the dorsal horn, and acts at supraspinal and peripheral sites.
Kinetics. Oral bioavailability about 30% (first pass); hepatic glucuronidation to morphine-6-glucuronide (active, more potent) and morphine-3-glucuronide (neuroexcitatory), both renally excreted.
Adverse effects.
- Respiratory depression (reduced CO2 sensitivity)
- Sedation, nausea, vomiting, constipation, pruritus, miosis
- Histamine release: hypotension, itch
- Accumulation of metabolites in renal failure
Titrate IV in small increments to effect. In renal failure prefer fentanyl.
Fentanyl
Synthetic phenylpiperidine opioid; mu agonist
Mechanism. Potent mu agonist, about 100 times morphine.
Kinetics. Highly lipid soluble: fast onset, short action after a bolus because of redistribution; accumulates with infusion (context-sensitive half-time rises). Hepatic CYP3A4 to inactive metabolites. Intranasal route useful in children.
Adverse effects.
- Respiratory depression
- Chest wall rigidity with large rapid doses
- Bradycardia
- Less histamine release and hypotension than morphine
Interactions.
- CYP3A4 inhibitors (clarithromycin, azoles, ritonavir) prolong its effect
- Serotonin toxicity with serotonergic drugs (weak)
Preferred in renal failure and haemodynamic instability.
Paracetamol
Analgesic and antipyretic
Mechanism. Not fully understood: central COX inhibition (peroxidase site, effective where peroxide tone is low), and serotonergic and cannabinoid pathways via the metabolite AM404. Little peripheral anti-inflammatory effect.
Kinetics. Oral bioavailability high; peak at 30 to 60 minutes; hepatic glucuronidation and sulfation; a small fraction via CYP2E1 to NAPQI, normally detoxified by glutathione.
Dose. Adult over 50 kg: 1 g orally or IV every 4 to 6 hours, maximum 4 g in 24 hours.
Adverse effects.
- Hepatotoxicity in overdose or with glutathione depletion (malnutrition, chronic alcohol)
- Hypotension with rapid IV infusion (rare)
Overdose is treated with acetylcysteine; see the antidote entry.
Lignocaine
Amide local anaesthetic; class Ib antiarrhythmic
Mechanism. Blocks voltage-gated Na channels from inside the cell, binding open and inactivated channels (use-dependent). Small, myelinated and actively firing fibres are blocked first.
Kinetics. pKa about 7.9: in inflamed (acidic) tissue less is un-ionised, so onset is slower. Hepatic metabolism (CYP1A2 and 3A4) to active metabolites. Adrenaline slows absorption, prolongs action and allows a larger dose.
Dose. Maximum dose commonly quoted for infiltration: about 3 mg/kg plain and 7 mg/kg with adrenaline.
Adverse effects.
- Systemic toxicity: perioral tingling, tinnitus, confusion, seizures, then arrhythmias and cardiovascular collapse
- Methaemoglobinaemia is mainly prilocaine and benzocaine, not lignocaine
Local anaesthetic systemic toxicity is treated with airway and seizure control, and lipid emulsion; see the antidote entry.